

Stefano Partelli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1887192/stefano-partelli-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

192
papers

5,654
citations

42
h-index

68
g-index

203
ext. papers

6,972
ext. citations

4.4
avg, IF

5.48
L-index

#	Paper	IF	Citations
192	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017 , 543, 65-71	50.4	482
191	Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 213-9	6.9	239
190	Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. <i>Surgery</i> , 2011 , 150, 75-82	3.6	238
189	Middle pancreatectomy: indications, short- and long-term operative outcomes. <i>Annals of Surgery</i> , 2007 , 246, 69-76	7.8	184
188	Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4784-9	5.6	164
187	ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2017 , 105, 255-265	5.6	136
186	Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis. <i>Gut</i> , 2017 , 66, 495-506	19.2	132
185	Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. <i>European Journal of Cancer</i> , 2012 , 48, 1608-15	7.5	122
184	Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). <i>JAMA Surgery</i> , 2013 , 148, 932-9	5.4	121
183	Resectable pancreatic cancer: who really benefits from resection?. <i>Annals of Surgical Oncology</i> , 2009 , 16, 3316-22	3.1	115
182	Total pancreatectomy: indications, different timing, and perioperative and long-term outcomes. <i>Surgery</i> , 2011 , 149, 79-86	3.6	92
181	Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections. <i>Archives of Surgery</i> , 2012 , 147, 261-6		91
180	Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. <i>British Journal of Surgery</i> , 2017 , 104, 34-41	5.3	86
179	Delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy: validation of International Study Group of Pancreatic Surgery classification and analysis of risk factors. <i>Hpb</i> , 2010 , 12, 610-8	3.8	85
178	A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2018 , 267, 1148-1154	7.8	81
177	Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. <i>American Journal of Surgery</i> , 2012 , 203, 132-9	2.7	79
176	Intraductal papillary mucinous neoplasms of the pancreas with multifocal involvement of branch ducts. <i>American Journal of Surgery</i> , 2009 , 198, 709-14	2.7	69

175	Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?. <i>European Journal of Surgical Oncology</i> , 2016 , 42, 1533-9	3.6	69
174	A systematic review on robotic pancreaticoduodenectomy. <i>Surgical Oncology</i> , 2013 , 22, 238-46	2.5	68
173	Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. <i>Surgery</i> , 2014 , 155, 145-53	3.6	67
172	Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. <i>Digestive and Liver Disease</i> , 2012 , 44, 945-51	3.3	64
171	Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67. <i>Annals of Surgical Oncology</i> , 2018 , 25, 2467-2474	3.1	63
170	Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. <i>Annals of Surgery</i> , 2013 , 257, 308-14	7.8	62
169	Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. <i>Neuroendocrinology</i> , 2010 , 92, 246-51	5.6	60
168	Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio. <i>Annals of Surgery</i> , 2010 , 251, 477-82	7.8	60
167	Laparoscopic rectal resection for severe endometriosis of the mid and low rectum: technique and operative results. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012 , 26, 1035-40	5.2	59
166	Prognosis of sporadic resected small (≤2cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. <i>Hpb</i> , 2018 , 20, 251-259	3.8	57
165	Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors. <i>Langenbecks Archives of Surgery</i> , 2014 , 399, 315-21	3.4	57
164	Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases. <i>Neuroendocrinology</i> , 2015 , 102, 68-76	5.6	57
163	Parenchyma-sparing resections for pancreatic neoplasms. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010 , 17, 782-7	2.8	54
162	Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. <i>Surgery</i> , 2016 , 159, 862-71	3.6	52
161	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. <i>Neuroendocrinology</i> , 2018 , 107, 375-386	5.6	52
160	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2094-100	3.1	48
159	Systematic review and meta-analysis of metal versus plastic stents for preoperative biliary drainage in resectable periampullary or pancreatic head tumors. <i>European Journal of Surgical Oncology</i> , 2016 , 42, 1278-85	3.6	48
158	Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. <i>Surgery</i> , 2018 , 163, 761-767	3.6	47

157	Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. <i>British Journal of Surgery</i> , 2012 , 99, 1234-40	5.3	46
156	Current status of robotic distal pancreatectomy: a systematic review. <i>Surgical Oncology</i> , 2013 , 22, 201-7	2.5	45
155	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 1197-205	8.8	44
154	The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors. <i>Neuroendocrinology</i> , 2014 , 100, 293-9	5.6	44
153	Differences between main-duct and branch-duct intraductal papillary mucinous neoplasms of the pancreas. <i>World Journal of Gastrointestinal Surgery</i> , 2010 , 2, 342-6	2.4	43
152	Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016 , 23, 981-989	3.1	42
151	Risk of misdiagnosis and overtreatment in patients with main pancreatic duct dilatation and suspected combined/main-duct intraductal papillary mucinous neoplasms. <i>Surgery</i> , 2016 , 159, 1041-9	3.6	39
150	Active Surveillance versus Surgery of Nonfunctioning Pancreatic Neuroendocrine Neoplasms \leq 2 cm in MEN1 Patients. <i>Neuroendocrinology</i> , 2016 , 103, 779-86	5.6	39
149	The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 778-783	3.6	38
148	Pancreaticojejunostomy is comparable to pancreaticogastrostomy after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. <i>Langenbeck's Archives of Surgery</i> , 2016 , 401, 427-37	3.4	38
147	Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 372-379	3.6	38
146	Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. <i>Pancreas</i> , 2014 , 43, 212-8	2.6	38
145	Enhanced recovery pathways in pancreatic surgery: State of the art. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6456-68	5.6	35
144	Evaluation of a predictive model for pancreatic fistula based on amylase value in drains after pancreatic resection. <i>American Journal of Surgery</i> , 2014 , 208, 634-9	2.7	34
143	Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review. <i>Advances in Medical Sciences</i> , 2016 , 61, 147-53	2.8	33
142	Perioperative and long-term results after left pancreatectomy: a single-institution, non-randomized, comparative study between open and laparoscopic approach. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011 , 25, 2871-8	5.2	33
141	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients. <i>Annals of Surgery</i> , 2019 , 270, 422-433	7.8	33
140	Early Postoperative Prediction of Clinically Relevant Pancreatic Fistula after Pancreaticoduodenectomy: usefulness of C-reactive Protein. <i>Hpb</i> , 2017 , 19, 580-586	3.8	32

139	Evaluation of an enhanced recovery protocol after pancreaticoduodenectomy in elderly patients. <i>Hpb</i> , 2016 , 18, 153-158	3.8	32
138	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , 2018 , 102, 95-102	7.5	32
137	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 309-24	7	30
136	Extent of surgical resections for intraductal papillary mucinous neoplasms. <i>World Journal of Gastrointestinal Surgery</i> , 2010 , 2, 347-51	2.4	30
135	The treatment of hyperinsulinemic hypoglycaemia in adults: an update. <i>Journal of Endocrinological Investigation</i> , 2017 , 40, 9-20	5.2	29
134	Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2017 , 12, e0179445	3.7	29
133	Clinical Usefulness of F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms. <i>Oncologist</i> , 2018 , 23, 186-192	5.7	29
132	Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection. <i>Annals of Surgical Oncology</i> , 2011 , 18, 3608-14	3.1	28
131	Long-term outcome after laparoscopic bowel resections for deep infiltrating endometriosis: a single-center experience after 900 cases. <i>BioMed Research International</i> , 2014 , 2014, 463058	3	27
130	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 111, 152-165	7	26
129	Systematic review and meta-analysis on laparoscopic pancreatic resections for neuroendocrine neoplasms (PNENs). <i>Expert Review of Gastroenterology and Hepatology</i> , 2017 , 11, 65-73	4.2	26
128	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1348-1355	3.1	26
127	Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. <i>Oncologist</i> , 2017 , 22, 409-415	5.7	25
126	Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?. <i>Surgery</i> , 2012 , 152, S112-9	3.6	24
125	Middle-preserving pancreatectomy for multicentric body-sparing lesions of the pancreas. <i>American Journal of Surgery</i> , 2009 , 198, e49-53	2.7	24
124	mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2016 , 23, 883-891	5.7	24
123	Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 264-74	7	23
122	Selection criteria in resectable pancreatic cancer: a biological and morphological approach. <i>World Journal of Gastroenterology</i> , 2014 , 20, 11210-5	5.6	23

121	Plasticity of human dedifferentiated adipocytes toward endothelial cells. <i>Experimental Hematology</i> , 2015 , 43, 137-46	3.1	23
120	Surgical treatment of pancreatic tumors in childhood and adolescence: uncommon neoplasms with favorable outcome. <i>Pancreatology</i> , 2011 , 11, 383-9	3.8	23
119	Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. <i>World Journal of Gastroenterology</i> , 2016 , 22, 9944-9953	5.6	23
118	Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1486-1494	5.6	22
117	Surgical management of neuroendocrine tumors. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016 , 30, 93-102	6.5	22
116	Right hemicolectomy plus pancreaticoduodenectomy vs partial duodenectomy in treatment of locally advanced right colon cancer invading pancreas and/or only duodenum. <i>Surgical Oncology</i> , 2014 , 23, 92-8	2.5	22
115	GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors. <i>European Journal of Endocrinology</i> , 2014 , 171, R153-62	6.5	22
114	A systematic review and meta-analysis of spleen-preserving distal pancreatectomy with preservation or ligation of the splenic artery and vein. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2016 , 14, 109-18	2.5	21
113	A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. <i>Hpb</i> , 2018 , 20, 197-203	3.8	20
112	Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life. <i>Surgery</i> , 2019 , 166, 157-163	3.6	19
111	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. <i>Neuroendocrinology</i> , 2016 , 103, 531-7	5.6	18
110	Portal vein embolization and ligation for extended hepatectomy. <i>Indian Journal of Surgical Oncology</i> , 2014 , 5, 30-42	0.7	18
109	Adequacy of lymph node retrieval for ampullary cancer and its association with improved staging and survival. <i>World Journal of Surgery</i> , 2013 , 37, 1397-404	3.3	17
108	Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas. <i>World Journal of Gastroenterology</i> , 2014 , 20, 10008-23	5.6	17
107	Is the Real Prevalence of Pancreatic Neuroendocrine Tumors Underestimated? A Retrospective Study on a Large Series of Pancreatic Specimens. <i>Neuroendocrinology</i> , 2019 , 109, 165-170	5.6	16
106	Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2018 , 13, e0197035	3.7	16
105	Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. <i>World Journal of Gastrointestinal Oncology</i> , 2016 , 8, 389-401	3.4	16
104	Single-incision laparoscopic cholecystectomy versus traditional laparoscopic cholecystectomy performed by a single surgeon: findings of a randomized trial. <i>Surgery Today</i> , 2016 , 46, 313-8	3	15

103	Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. <i>World Journal of Surgery</i> , 2018 , 42, 3223-3230	3.3	15
102	Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre. <i>Hpb</i> , 2013 , 15, 958-64	3.8	15
101	Risk and Predictors of Postoperative Morbidity and Mortality After Pancreaticoduodenectomy for Pancreatic Neuroendocrine Neoplasms: A Comparative Study With Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2019 , 48, 504-509	2.6	15
100	Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3. <i>American Journal of Surgery</i> , 2020 , 220, 284-289	2.7	14
99	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , 2018 , 18, 198-203	3.8	14
98	Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2021 , 111, 273-287	5.6	13
97	The role of (18)fluoro-deoxyglucose positron emission tomography/computed tomography in resectable pancreatic cancer. <i>Digestive and Liver Disease</i> , 2014 , 46, 744-9	3.3	13
96	Extent of Surgery and Implications of Transection Margin Status after Resection of IPMNs. <i>Gastroenterology Research and Practice</i> , 2014 , 2014, 269803	2	13
95	Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). <i>Clinical and Translational Imaging</i> , 2019 , 7, 181-188	2	12
94	Implications of increased serum amylase after pancreaticoduodenectomy: toward a better definition of clinically relevant postoperative acute pancreatitis. <i>Hpb</i> , 2020 , 22, 1645-1653	3.8	12
93	Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). <i>Annals of Surgical Oncology</i> , 2021 , 28, 7506-7517	3.1	12
92	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2019 , 9, 18614	4.9	12
91	Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 24-30	3.6	12
90	A systematic review and meta-analysis on the role of omental or falciform ligament wrapping during pancreaticoduodenectomy. <i>Hpb</i> , 2020 , 22, 1227-1239	3.8	11
89	Management of rectosigmoid obstruction due to severe bowel endometriosis. <i>Updates in Surgery</i> , 2014 , 66, 59-64	2.9	11
88	Ezrin expression is an independent prognostic factor in gastro-intestinal cancers. <i>Journal of Gastrointestinal Surgery</i> , 2013 , 17, 2082-91	3.3	11
87	Rectal indomethacin to prevent post-ERCP pancreatitis. <i>New England Journal of Medicine</i> , 2012 , 367, 277-8; author reply 278-9	59.2	11
86	Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. <i>Nuclear Medicine Communications</i> , 2020 , 41, 896-905	1.6	11

85	The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age. <i>Digestive and Liver Disease</i> , 2019 , 51, 735-740	3.3	10
84	Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. <i>Translational Oncology</i> , 2019 , 12, 1-7	4.9	10
83	Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2020 , 27, 3928-3936	3.1	10
82	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017 , 6, 1493-1499	4.8	9
81	The natural history of a branch-duct intraductal papillary mucinous neoplasm of the pancreas. <i>Surgery</i> , 2014 , 155, 578-9	3.6	9
80	Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 1524-1531	3.6	8
79	SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer. <i>Digestive and Liver Disease</i> , 2018 , 50, 84-90	3.3	8
78	Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. <i>Annals of Oncology</i> , 2012 , 23, 1928	10.3	8
77	R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021 , 28, 4602-4612	3.1	8
76	Long-Term Pancreatic Functional Impairment after Surgery for Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	7
75	Local treatment for focal progression in metastatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2019 , 26, 405-409	5.7	7
74	Preoperative predictive factors of laparoscopic distal pancreatectomy difficulty. <i>Hpb</i> , 2020 , 22, 1766-1774	3.4	7
73	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) \geq 1 cm: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , 2020 , 7, 598438	4.9	7
72	Outcomes after distal pancreatectomy for neuroendocrine neoplasms: a retrospective comparison between minimally invasive and open approach using propensity score weighting. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021 , 35, 165-173	5.2	7
71	Update on gastroenteropancreatic neuroendocrine tumors. <i>Digestive and Liver Disease</i> , 2021 , 53, 171-183	3.3	7
70	Larger hepatic metastases are more frequent with N0 colorectal tumours and are associated with poor prognosis: implications for surveillance. <i>International Journal of Surgery</i> , 2010 , 8, 453-7	7.5	6
69	Surgical management of pancreatic neuroendocrine neoplasms. <i>Annals of Saudi Medicine</i> , 2014 , 34, 1-5	1.6	6
68	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. <i>Surgical Oncology</i> , 2020 , 35, 141-148	2.5	6

67	Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 4002-4015	8.8	6
66	Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study. <i>Frontiers in Oncology</i> , 2019 , 9, 1299	5.3	6
65	Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?. <i>Surgery</i> , 2021 , 169, 403-410	3.6	6
64	Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT). <i>Endocrine Pathology</i> , 2020 , 31, 119-131	4.2	5
63	MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells. <i>Neuroendocrinology</i> , 2021 , 111, 739-751	5.6	5
62	Pancreatic Surgery. <i>Frontiers of Hormone Research</i> , 2015 , 44, 139-48	3.5	5
61	Alteration in emergency theatre prioritisation does not alter outcome for acute appendicitis: comparative cohort study. <i>World Journal of Emergency Surgery</i> , 2009 , 4, 22	9.2	5
60	Main Duct Thresholds for Malignancy Are Different in Intraductal Papillary Mucinous Neoplasms of the Pancreatic Head and Body-Tail. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	5
59	Evidence of a common cell origin in a case of pancreatic mixed intraductal papillary mucinous neoplasm-neuroendocrine tumor. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 478, 1215-1219	5.1	5
58	The impact of minimally invasive surgery on hospital readmissions, emergency department visits and functional recovery after distal pancreatectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021 , 35, 5740-5751	5.2	5
57	Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). <i>Pancreatology</i> , 2019 , 19, 57-63	3.8	5
56	Endoscopic ultrasound appearance of pancreatic serotonin-staining neuroendocrine neoplasms. <i>Pancreatology</i> , 2018 , 18, 792-798	3.8	5
55	Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. <i>Annals of Surgical Oncology</i> , 2021 , 28, 8249-8260	3.1	5
54	Pancreatic Ductal Adenocarcinoma: A New TNM Staging System is Needed!. <i>Annals of Surgery</i> , 2017 , 266, e108-e109	7.8	4
53	Neuroendocrine tumours in 2016: Defining rules for increasingly personalized treatments. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 80-82	19.4	4
52	Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma. <i>BJS Open</i> , 2019 , 3, 646-655	3.9	4
51	How should incidental NEN of the pancreas and gastrointestinal tract be followed?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018 , 19, 139-144	10.5	4
50	Pancreatic cystic neoplasms: What is the most cost-effective follow-up strategy?. <i>Endoscopic Ultrasound</i> , 2018 , 7, 319-322	3.6	4

49	A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. <i>Updates in Surgery</i> , 2020 , 72, 39-45	2.9	4
48	Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis. <i>British Journal of Surgery</i> , 2021 , 108, 811-816	5.3	4
47	Preoperative risk stratification of postoperative pancreatic fistula: A risk-tree predictive model for pancreatoduodenectomy. <i>Surgery</i> , 2021 , 170, 1596-1601	3.6	4
46	Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms. <i>Diagnostics</i> , 2021 , 11,	3.8	4
45	Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2021 , 111, 728-738	5.6	3
44	Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms. <i>Current Treatment Options in Oncology</i> , 2020 , 21, 48	5.4	3
43	Pleomorphic liposarcoma of the axilla metastatic to the pancreas. <i>Digestive Surgery</i> , 2009 , 26, 262-3	2.5	3
42	Disease-free survival as a measure of overall survival in resected pancreatic endocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2020 , 27, 275-283	5.7	3
41	Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma: Legend or Scientific Evidence?. <i>Annals of Surgical Oncology</i> , 2021 , 28, 2312-2322	3.1	3
40	The role of acinar content at pancreatic resection margin in the development of postoperative pancreatic fistula and acute pancreatitis after pancreaticoduodenectomy. <i>Surgery</i> , 2021 , 170, 1215-1222 ^{3.6}	3.6	3
39	Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis. <i>Journal of Endocrinological Investigation</i> , 2021 , 45, 705	5.2	2
38	Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: Possible clinical impact of misclassification. <i>Endoscopic Ultrasound</i> , 2021 , 10, 372-380	3.6	2
37	Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology. <i>Hpb</i> , 2021 , 23, 1666-1673	3.8	2
36	Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 1258-1266	3.6	2
35	A tug-of-war in intraductal papillary mucinous neoplasms management: Comparison between 2017 International and 2018 European guidelines. <i>Digestive and Liver Disease</i> , 2021 , 53, 998-1003	3.3	2
34	Duodeno-jejunal or gastro-enteric leakage after pancreatic resection: a case-control study. <i>Updates in Surgery</i> , 2019 , 71, 295-303	2.9	1
33	ASO Author Reflections: Circulating Neuroendocrine Gene Transcripts (NETest): A Promising Biomarker for Pancreatic Neuroendocrine Tumours (PanNET). <i>Annals of Surgical Oncology</i> , 2020 , 27, 3937-3938 ¹	3.1	1
32	The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2020 , 14, 1179554920936605	1.8	1

31	Comment on "predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine". <i>Surgery</i> , 2014 , 155, 582-4	3.6	1
30	Portal vein embolisation for extended hepatectomy: single-centre experience. <i>Journal of Gastrointestinal Cancer</i> , 2012 , 43, 413-9	1.6	1
29	SILS cholecystectomy, early experience of a single institution: pilot study of 21 cases. <i>Updates in Surgery</i> , 2012 , 64, 145-8	2.9	1
28	Impact of enhanced recovery protocols after pancreatoduodenectomy: meta-analysis.. <i>British Journal of Surgery</i> , 2022 ,	5.3	1
27	EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). <i>Cancers</i> , 2021 , 13,	6.6	1
26	Which is the best pancreatic anastomosis?. <i>Minerva Chirurgica</i> , 2019 , 74, 241-252	0.8	1
25	Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors. <i>Surgery</i> , 2020 , 168, 816-824	3.6	1
24	Indications to total pancreatectomy for positive neck margin after partial pancreatectomy: a review of a slippery ground. <i>Updates in Surgery</i> , 2021 , 73, 1219-1229	2.9	1
23	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 46-51	3.6	1
22	Evaluation of cost-effectiveness among open, laparoscopic and robotic distal pancreatectomy: A systematic review and meta-analysis. <i>American Journal of Surgery</i> , 2021 , 222, 513-520	2.7	1
21	Role of Minimally Invasive Surgery in the Treatment of Pancreatic Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018 , 141-147	0.1	0
20	How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.. <i>Current Oncology Reports</i> , 2022 , 24, 227	6.3	0
19	Early biochemical predictors of clinically relevant pancreatic fistula after distal pancreatectomy: a role for serum amylase and C-reactive protein.. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022 , 1	5.2	0
18	Role of chromogranin A-derived fragments after resection of nonfunctioning pancreatic neuroendocrine tumors.. <i>Journal of Endocrinological Investigation</i> , 2022 , 1	5.2	0
17	Evaluation of factors predicting loss of benefit provided by laparoscopic distal pancreatectomy compared to open approach. <i>Updates in Surgery</i> , 2021 , 1	2.9	0
16	Portal vein resection during pancreaticoduodenectomy for pancreatic neuroendocrine tumors. An international multicenter comparative study. <i>Surgery</i> , 2021 , 169, 1093-1101	3.6	0
15	Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022 , 1	8.8	0
14	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.. <i>JAMA Network Open</i> , 2022 , 5, e220290 ^{10.4}	10.4	0

- 13 Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases.. *Endocrine Pathology*, **2022**, 1 4.2 0
- 12 Guideline for the Management of Pancreatic Neuroendocrine Tumor **2017**, 161-172
- 11 Questions about branch-duct IPMNs with Sendai negative criteria. *Annals of Surgery*, **2014**, 259, e42 7.8
- 10 Surgical Therapy of Pancreatic Neuroendocrine Neoplasms **2015**, 185-190
- 9 Pancreatic Neuroendocrine Tumours **2018**, 333-343
- 8 Functional imaging tests and CT scan: Detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up.. *Journal of Clinical Oncology*, **2016**, 34, 219-219 2.2
- 7 Therapy for Locoregional Disease: Pancreas **2018**, 235-254
- 6 Surgical Therapy. *Updates in Surgery Series*, **2013**, 109-116 0.1
- 5 Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors **2021**, 631-640
- 4 New Surgical Strategies **2021**, 113-128
- 3 Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma?. *Digestive and Liver Disease*, **2021**, 53, 1065-1067³
- 2 Non Functional Pancreatic Neuroendocrine Tumors **2021**, 125-135
- 1 Preoperative risk stratification of postoperative pancreatic fistula: A risk-tree predictive model for pancreatoduodenectomy. *Annals of Hepato-biliary-pancreatic Surgery*, **2022**, 26, S66-S66 1.5